SUBSCRIBE
SUBSCRIBE
News   FDA

Bristol-Myers Squibb Company: ONGLYZATM (saxagliptin) Receives Marketing Authorisation In Europe For The Treatment Of Type 2 Diabetes

October 5, 2009 | 
1 min read
PARIS & LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE/LSE: AZN) announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union.
FDA Approvals Europe
Bristol Myers Squibb Company
MORE ON THIS TOPIC
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
 · 
2 min read
 · 
Jef Akst
Illustration showing businessman trying to create his own road
FDA
Compass vows to press on with FDA application despite new trial request
September 22, 2026
 · 
3 min read
 · 
Annalee Armstrong
Creative development success and Innovation breakthrough progress as a Business advancement concept or growth strategy for taking off as a motivational metaphor for adaptation and goals focus.
Rare diseases
Mikhail, Davis on board with regulatory framework tailored to rare disease therapies
September 21, 2026
 · 
6 min read
 · 
Heather McKenzie
Money or health. Scale of balance between money, dollar and medicine, pill. Cost of health. Compare of price healthcare and healthy. Seesaw between wealth and healthy. Treatment or savings. Vector.
Approvals
Ultragenyx wins FDA greenlight for first Sanfilippo therapy, priced at nearly $4M
September 18, 2026
 · 
3 min read
 · 
Tristan Manalac